Ibex Investors’s Exact Sciences EXAS Stock Holding History

Ibex Investors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,679	Closed	-$232K	–	84
2018 Q4	$232K	Buy	+3,679	New	+$252K	0.04%	68

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Ibex Investors's EXAS Position: Q1 2019 in Review

Ibex Investors sold out of Exact Sciences (EXAS) in Q1 2019, closing a stake of 3,679 shares — an estimated $232K sold.

Ibex Investors first reported a position in EXAS in Q4 2018 and held it in 1 quarter. The position peaked at $232K in Q4 2018. 424 funds tracked by Wall St. Rank hold EXAS as of Q1 2019.

Ibex Investors reported no remaining Exact Sciences position as of Q1 2019 after selling out during the quarter.
Ibex Investors sold 3,679 Exact Sciences shares in Q1 2019, an estimated $232K.
Ibex Investors first reported a position in Exact Sciences in Q4 2018 and held it in 1 quarter.
Ibex Investors's Exact Sciences position peaked at $232K in Q4 2018.
424 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.